Ramana
Chepuri Venkata Ramana, Pune IN
Patent application number | Description | Published |
---|---|---|
20140187639 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof - Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular PH domains. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL and with other Akt inhibitors in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided. | 07-03-2014 |
Chodimella Venkata Ramana, Murugeshpalya IN
Patent application number | Description | Published |
---|---|---|
20110135027 | CHAOTIC WIDE BAND FREQUENCY MODULATOR FOR NOISE REDUCTION - The embodiments of the invention relate to apparatus and method for reducing electromagnetic interference (EMI) and radio frequency interference (RFI) in computer systems via a chaotic wide band frequency modulation. The chaotic noise modulator, in one embodiment, comprises: a master cell to generate a control voltage corresponding to an un-modulated reference signal; and a slave cell having a chaotic signal generator to generate a random noise signal, the slave cell coupled with the master cell and operable to generate a modulated output signal in response to the control voltage. | 06-09-2011 |
C. V. Ramana, Pune IN
Patent application number | Description | Published |
---|---|---|
20120016033 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof - Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular PH domains. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL and with other Akt inhibitors in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided. | 01-19-2012 |
Kanniganti Venkata Ramana, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20140214286 | SYSTEM AND METHOD FOR TRANSMITTING HELICOPTER HEALTH AND LOCATION - A system and method combines integrated system health usage monitoring and flight tracking of a helicopter, and transmits the information to monitoring sites for managing flight operations in real time, thereby providing the functionality of both system health and flight tracking and reducing weight related constraints faced by helicopters. With enhanced availability of system health data, vital information for maintenance and flight position data-stream, operations, flight dispatch and maintenance can plan for required services more efficiently. | 07-31-2014 |
Kolla Venkata Ramana, Andhra Pradesh IN
Patent application number | Description | Published |
---|---|---|
20150364051 | GENERATING A COMPREHENSION INDICATOR THAT INDICATES HOW WELL AN INDIVIDUAL UNDERSTOOD THE SUBJECT MATTER COVERED BY A TEST - A method and system are provided for generating a comprehension indicator that indicates how well an individual understood the subject matter covered by a test. In one implementation, a question-level comprehension indicator is generated for each of the questions on the test. The question-level comprehension indicators may be generated based upon one or more question-level factors, which may include behavioral aspects of the individual while taking the test. After the question-level comprehension indicators are generated, they may be used to generate a first test-level comprehension indicator. A second test-level comprehension indicator may also be generated. Unlike the first test-level comprehension indicator, the second test-level comprehension indicator is generated based upon test level rather than question level factors. After the first and second test-level comprehension indicators are generated, they may be used to derive an overall comprehension indicator for the individual for that test. The overall comprehension indicator may then be used in addition to or in lieu of a test score to determine how well the individual understood the subject matter covered by the test, as well as other purposes. | 12-17-2015 |
Kota V. Ramana, Galveston, TX US
Patent application number | Description | Published |
---|---|---|
20090270490 | METHODS INVOLVING ALDOSE REDUCTASE INHIBITION - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including inflammatory bowel disease, macular degeneration, or posterior capsule opacification. | 10-29-2009 |
20100016404 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE - Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be a small-interfering RNA (siRNA) or may be inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure. Also, methods of treating a cancer or suppressing metastasis thereof using the siRNAs and aldose reductase inhibitors are provided. | 01-21-2010 |
20100022625 | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use - Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors for inhibition of glutathione-aldehyde binding to aldose reductase. In addition methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using a small interfering RNA (siRNA) or the designed inhibitors. | 01-28-2010 |
20110092566 | Treatment of cancer with aldose reductase inhibitors - Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be small molecules such as fidarestat or siRNA. Also, methods of treating breast and prostate cancers or suppressing metastasis of colon cancer thereof using the siRNAs and aldose reductase inhibitors are provided. | 04-21-2011 |
20120238609 | Methods for Treating COPD - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for treating COPD. | 09-20-2012 |
20130023529 | Methods Involving Aldose Reductase Inhibitors - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma. | 01-24-2013 |
20130096111 | Methods Involving Aldose Reductase Inhibitors - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma. | 04-18-2013 |
20140206693 | COMPOSITIONS AND METHODS FOR TREATING COLON CANCER - Certain embodiments are directed to methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using an aldose reductase specific inhibitor. | 07-24-2014 |
Reddy M. V. Ramana, Blue Bell, PA US
Patent application number | Description | Published |
---|---|---|
20100022615 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS - Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions. | 01-28-2010 |
Venkata P. Ramana, Visakhapatnam IN
Patent application number | Description | Published |
---|---|---|
20120232274 | PROCESS FOR PREPARATION OF CLOPIODOGREL BISULFATE FORM-1 - An improved process for preparing crystalline form-1 of (S)-methyl 2-(2-chlorophenyl)-2-{6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl}acetate bisulfate (clopidogrel bisulfate) of formula I is provided The preparation comprises the straight conversion of an uncyclized material of (S)-methyl 2-[2-(thiophen-2-yl)ethylamino]-2-(2-chlorophenyl) acetate hydrochloride into clopidogrel bisulfate crystalline form-1 without any degradation of clopidogrel base | 09-13-2012 |